Joseph J. Eron, MD
Co-Director, Clinical Trials Unit (CTU)
Director, CFAR Clinical Core
Chief, Division of Infectious Diseases
Herman and Louise Smith Distinguished Professor of Medicine
Areas of Interest
Antiretroviral therapy, resistance, pharmacology, transmission and HIV persistence and disruption of latency
About
Dr. Eron is Principal Investigator of the HIV/AIDS Clinical Research Unit at UNC-CH and Director of the Clinical Core for the UNC Center for AIDS Research (CFAR). He has been part of the AIDS Clinical Trials Group since 1993 and has held multiple leadership positions including Chair of the Optimization of ART Committee and the Cure Transformative Science Group. He is the Principal Investigator of the UNC Clinical trials Unit with sites in Chapel Hill, Greensboro, Lilongwe, Malawi and Hanoi, Vietnam. In addition, he is a leader of the UNC Acute HIV Infection research team and a collaborator in the UNC HIV Cure Center. Over the last 15 years, Dr. Eron has led the development of the UNC HIV CFAR clinic cohort that includes over 5,000 HIV infected individuals and has active collaboration and membership in the NA ACCORD and CNICS cohorts. Dr. Eron has over 400 publications in peer-reviewed journals focusing on antiretroviral therapy, resistance, pharmacology, transmission and HIV persistence, and disruption of latency. Recent work has included publications from the UNC-CFAR HIV Clinical Cohort, the ACTG, HPTN and IAS-USA HIV treatment guidelines in JAMA, 2020. Dr. Eron has worked extensively in the area of HIV drug development and led or participated in original studies of many antiretroviral therapies. He also continues as an active HIV infectious disease clinician. He is now the leader of the ACTG Scientific Agenda Steering Committee and is Vice Chair (co-PI) of the ACTG network.
In the news
William A. Fischer II, MD, Director of Emerging Pathogens at UNC’s Institute for Global Health and Infectious Diseases and Joe Eron, MD, UNC Chief of Infectious Diseases and chair of the ACTG, co-authored a study that found tecovirimat used to treat mpox does not shorten time to lesion resolution, reduce pain, or speed viral clearance … Read more A trial led by Joe Eron, MD, a researcher with the UNC Institute for Global Health and Infectious Diseases, marks a significant milestone toward what could become the first complete long‑acting HIV regimen requiring dosing only twice per year. This new report is considered the first Phase 2 study to evaluate a complete HIV‑1 treatment … Read more Chapel Hill, N.C. — A Phase 2 study led by Dr. Joe Eron, a member of the UNC Institute for Global Health and Infectious Diseases, shows an investigational once‑weekly, all‑oral combination of islatravir (ISL) and lenacapavir(LEN) maintains high levels of virologic suppression through 48 weeks in adults living with HIV. Published in the Annals of … Read more In a commentary published by Nature Medicine, Dr. Myron Cohen and Dr. Joe Eron, leaders of the UNC Institute for Global Health and Infectious Diseases, identify numerous medical advances originating from U.S. federally funded HIV research. They say the future of HIV research and the U.S.’s scientific leadership depends on bold, sustained action in defense … Read more
Key International Mpox Trial Finds No Clinical Benefit from Tecovirimat
Twice‑Yearly Injectable HIV Regime Treatment Demonstrates Strong Efficacy and Safety
New Once Weekly Investigational Oral Regimen Shows Strong 48 Week Results, Highlighting the Need for Easier HIV Treatment Options
How HIV Research Drives Health Innovation in Multiple Diseases
-
Undergraduate
Harpur College
-
Medical School
Harvard Medical School
-
Residency
Massachusetts General Hospital, Harvard Medical School
-
Fellowship
Massachusetts General Hospital, Harvard Medical School